Ifp Advisors, Inc Cellectis S.A. Transaction History

Ifp Advisors, Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 06, 2021	SELL	$11.94 - $16.09 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$14.36 - $20.93 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	SELL	$18.19 - $33.25 $3,638 - $6,650	-200 Closed	0 $0
Q4 2020 Jan 25, 2021	BUY	$15.87 - $31.64 $3,174 - $6,328	200 New	200 $5,000
Q3 2020 Oct 29, 2020	BUY	$15.7 - $20.84 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	BUY	$8.21 - $21.02 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$7.81 - $18.82 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	BUY	$9.73 - $19.31 $0 - $0	0 New	0 $0
Q3 2019 Nov 07, 2019	BUY	$10.15 - $16.89 $0 - $0	0 New	0 $0
Q1 2019 May 15, 2019	SELL	$15.53 - $19.75 $3,106 - $3,950	-200 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$27.78 - $38.53 $4,167 - $5,779	-150 Reduced 42.86%	200 $0
Q1 2018 Jun 03, 2019	SELL	$27.78 - $35.19 $8,334 - $10,557	-300 Reduced 46.15%	350 $10,000
Q1 2018 May 09, 2018	BUY	$27.78 - $35.19 $8,334 - $10,557	300 Added 85.71%	650 $0
Q4 2017 Jan 24, 2018	BUY	$23.33 - $35.01 $8,165 - $12,253	350	350 $0

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.